Quantcast

Latest Glenmark Pharmaceuticals Limited Stories

2014-08-20 08:27:31

MUMBAI, August 20, 2014 /PRNewswire/ -- Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announces the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecific antibody. GBR 1302 was discovered and developed by the Glenmark Biologics Research Centre located in La Chaux-de-Fonds, Switzerland. GBR 1302 is based on Glenmark's innovative BEAT antibody...

2014-07-24 12:27:34

MUMBAI, India, July 24, 2014 /PRNewswire/ -- Consolidated Net Profit increased by 43.65 % to Rs. 1848.46 Mn Business Highlights - India Business grew by 20.87% to Rs. 3,971.59 Mn - US Business grew by 9.33% to Rs. 4,886.70 Mn - Rest of World (ROW) Business grew by 20.67% to Rs. 2,113.09 Mn - Europe Formulations Business grew by 34.53% to Rs. 977.26 Mn - Latin America Business grew by 33.92% to Rs. 1,176.45 Mn...

2014-06-04 08:29:36

MUMBAI and LA CHAUX-DE-FONDS, Switzerland, June 4, 2014 /PRNewswire/ -- - State-of-the-art Manufacturing Facility for Supply of Clinical Trial Material - With the Facility Glenmark has end-to-end Capabilities for the Development of Novel, State-of-the-art Monoclonal Antibodies Including Bi-specific Antibodies Glenmark Pharmaceuticals S.A (GPSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals Limited, India (GPL), announced the opening of its new cGMP...

2011-05-16 09:32:00

MUMBAI, India, May 16, 2011 /PRNewswire-FirstCall/ -- Glenmark Pharmaceuticals S.A (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announced today that it has entered into an agreement with Sanofi to grant Sanofi a license for the development and commercialization of GBR 500, a novel monoclonal antibody for the treatment of Crohn's Disease and other inflammatory conditions. The transaction is expected to close in the coming month subject to customary...

2010-05-03 12:00:00

WOODCLIFF LAKE, N.J., May 3 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that its generic division, Par Pharmaceutical, has entered into an exclusive licensing agreement with Glenmark Generics Limited and Glenmark Generics Inc., USA to market ezetimibe 10 mg tablets, the generic version of Merck & Co. Inc.'s Zetia, in the U.S. Zetia is a cholesterol modifying agent with annual U.S. sales of approximately $1.4 billion, according to IMS Health...

2009-07-23 05:14:00

MUMBAI, July 23 /PRNewswire-FirstCall/ -- - A Police Complaint has Been Lodged by Hospital Authorities Citing Fraudulent Activity by the Clinical Investigator Dr. A Bhattacharya Working at the GG Hospital and the MP Shah Medical College - Glenmark Not Only Acts as the Whistle-Blower but Also Discontinues its Clinical Study at the Mentioned Site After receiving approval from the Drug Controller General of India(DCGI) for a multi-centre Phase IIb clinical study for its lead...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related